In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines

Shigeki Ikubo, Nagio Takigawa, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Takuo Shibayama, Masakazu Chikamori, Keisuke Aoe, Akio Matsushita, Mine Harada

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The improvement of treatment outcome of small-cell lung cancer (SCLC), and search for new effective drugs and to overcome drug-resistance are essential. Materials and methods: We evaluated the cytotoxicity of antimicrotubule agents to seven human SCLC cell lines consisting of one cell line (SBC-3) established from a previously untreated patient as a representative of drug-sensitive cell line, three cell lines (SBC-2, SBC-4, and -7) derived from treated patients as representatives of intrinsic drug-resistant cell lines, and three drug-resistant sublines (SBC-3/ADM, SBC-3/ETP, and SBC-3/CDDP) selected by continuous exposure of the SBC-3 cell line to increasing concentrations of doxorubicin, etoposide, or cisplatin as representatives of acquired drug-resistant cell lines. Results: IC50 values for SBC-2, -3, -4, and -7 cells of antimicrotubule agents were markedly lower than those of doxorubicin, etoposide, and cisplatin. Both SBC-3/ADM and SBC-3/ETP subline were highly resistant to paclitaxel, docetaxel, vinorelbine, vincristine, vindesine, and vinblastine. However, an SBC-3/ADM subline was not fully cross-resistant to rhizoxin, and an SBC-3/ETP subline was as sensitive to rhizoxin as an SBC-3 cell line. A cisplatin-resistant subline, SBC-3/CDDP, showed no cross-resistance to the antimicrotubule agents. Conclusion: These results suggest that antimicrotubule agents are useful for SCLC, and rhizoxin may be particularly effective in the salvage treatment of refractory or relapsed patients.

Original languageEnglish
Pages (from-to)3985-3988
Number of pages4
JournalAnticancer Research
Volume19
Issue number5 B
Publication statusPublished - 1999

    Fingerprint

Keywords

  • Antimicrotubule agents
  • Drug resistance
  • MTT assay
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ikubo, S., Takigawa, N., Ueoka, H., Kiura, K., Tabata, M., Shibayama, T., Chikamori, M., Aoe, K., Matsushita, A., & Harada, M. (1999). In vitro evaluation of antimicrotubule agents in human small-cell lung cancer cell lines. Anticancer Research, 19(5 B), 3985-3988.